Legend Biotech reports early trial results for in vivo CAR-T therapy

June 15, 2026 8:00 AM

Legend Biotech Corporation (NASDAQ: LEGN) announced clinical trial data for LB2501, an investigational in vivo CAR-T cell therapy targeting CD19/CD20 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found